Search results
Results from the WOW.Com Content Network
By the end of December 2021, 758,891 doses had been administered and 583,609 persons (25% of the targeted population) were fully vaccinated. By the end of March 2022, 818,931 doses had been administered and 640,464 persons were fully vaccinated. By the end of April 2022, 831,318 doses had been administered and 652,422 persons were fully vaccinated.
Phases 2 and 3 clinical trials of COVAX-19 are being conducted in Iran under a co-operation agreement. [8] Phase 2 clinical trials started in May 2021 and Phase 3 trials commenced in August 2021. In the phase 2 trials, 400 Iranian volunteers were injected with either a placebo or the first dose of the vaccine.
In November 2021, Moderna CEO Stéphane Bancel claimed that the company had a backlog of tens of millions of doses of its vaccine destined for Africa because COVAX or individual governments could not take delivery. He cited delays with dose administration, a shortage of refrigerator space, and delays getting customs documents.
COVAX began distributing vaccines in February 2021. Though COVAX promised 100 million doses by the end of March, [3] [4] this goal was not reached until 6 July. [5] By mid-August 2021, COVAX delivered 200 million vaccine doses to nearly 140 countries instead of the 600 million doses initially projected.
3.8% of the Nigerian population fully vaccinated Website nphcda.gov.ng As of 28 February 2022 Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June ...
In March 2022, Ocugen registered a Phase 2/3 trial for 400 people in the US to compare the immune responses to those in people in the Indian phase 3 trial, as well as safety and tolerability. [44] The trial also aims to assess the vaccine as a booster after other Covid vaccines used in the US.
In April 2022, a Singapore study by infectious diseases experts from the National Centre for Infectious Diseases and the Ministry of Health found that CoronaVac recipients were 4.59 times more likely to have severe COVID-19 as well as 2.37 times more likely to be infected, compared to those who took the Pfizer-BioNTech vaccine.
Johnson & Johnson anticipated providing up to five hundred million doses through 2022 for COVAX. [63] [140] [141] The World Health Organization issued an EUL for the Janssen COVID‑19 vaccine Ad26.COV2.S vaccine in March 2021. [142] [143] In February 2021, the vaccine received emergency authorization in South Africa.